Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug 26:3:101-11.
doi: 10.2147/BCTT.S21741.

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer

J Menis  1 , C Twelves  2
Affiliations
Review

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer

J Menis et al. Breast Cancer (Dove Med Press). .

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Breast Cancer (Dove Med Press). 2011 Dec 30;4:1. doi: 10.2147/BCTT.S26170. eCollection 2011. Breast Cancer (Dove Med Press). 2011. PMID: 24367187 Free PMC article.

Abstract

Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used in this setting, but with little evidence of clinically relevant benefit, and none have previously shown improved survival. Eribulin (Halaven®) is a nontaxane tubulin-binding agent with a novel mode of action, and was recently approved by the European Medicines Agency and US Food and Drug Agency as a single agent for patients with heavily pretreated metastatic breast cancer. This review provides an overview of the discovery, and preclinical and clinical development of eribulin, culminating in the recently published EMBRACE metastatic breast cancer study.

Keywords: eribulin; metastatic breast cancer; pretreated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Halichondria okadai, Halichondrin B and eribulin mesylate.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(Suppl 1):S70–S80. - PubMed
    1. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44–52. - PubMed
    1. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–3277. - PubMed
    1. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 2009;27:4798–4808. - PubMed